CB2 Receptor Modulating Compounds for Selective Anti-Inflammatory Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic applications of cannabinoids are limited by their psychoactive effects, and there is a need for compounds that can selectively target the CB2 receptor to treat inflammation and pain without affecting the central nervous system.
Innovation Solution
Development of novel compounds that bind to and modulate the CB2 receptor, acting as agonists to treat inflammation and pain by administering therapeutic amounts, thereby avoiding the psychoactive effects associated with CB1 receptor activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cannabinoids are used for therapeutic applications, then anti-inflammatory and analgesic effects are achieved, but psychoactive side effects occur due to CB1 receptor activation
Solution Approach 1:
The invention segments the cannabinoid receptor system into two distinct targets: CB1 receptors in the central nervous system (responsible for psychoactive effects) and CB2 receptors in the immune system (responsible for therapeutic effects). By developing compounds that selectively target only CB2 receptors, the patent separates the desired therapeutic function from the unwanted psychoactive side effects, allowing treatment of inflammatory conditions without central nervous system involvement.
Solution Approach 2:
The patent applies local quality by creating compounds with selective affinity for CB2 receptors specifically located in immune cells and peripheral tissues. The chemical structures are designed to interact preferentially with CB2 receptors in the immune system while having minimal or no interaction with CB1 receptors in the brain, thereby providing localized therapeutic action at the periphery without affecting central psychoactive pathways.
2Adaptability or versatility
If CB1 selective agonists are used, then central nervous system effects are achieved, but therapeutic selectivity for immune system is lost
Solution Approach 1:
The invention segments the receptor targeting approach by designing compounds that exclusively or preferentially bind to CB2 receptors rather than CB1 receptors. This segmentation allows the therapeutic agent to act specifically on immune system components while leaving central nervous system receptors untouched, achieving both selectivity and therapeutic effectiveness for inflammatory conditions.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of cannabinoid compounds to alter their receptor binding profile. Specifically, structural modifications are made to increase affinity and selectivity for CB2 receptors while decreasing affinity for CB1 receptors, thereby changing the pharmacological parameters to achieve desired therapeutic selectivity and effectiveness.
Data Source
AI summary
Compounds of formula (I)are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.